Alvotech, Advanz Pharma get EU nod for Eylea biosimilar

[Biosimilars pharmaceutical drug bottle on blue background. A safe biological drug that work like biologic medicine. 3d illustration.]
Carl Lokko/iStock via Getty Images

* Alvotech (NASDAQ:ALVO [https://seekingalpha.com/symbol/ALVO]) and UK headquartered Advanz Pharma said that the European Commission has approved Mynzepli as a biosimilar to Regeneron's (REGN [https://seekingalpha.com/symbol/REGN]) Eylea (aflibercept), in a pre-filled syringe and vial.
* The companies stated [https://seekingalpha.com/pr/20207474-advanz-pharma-and-alvotech-receive-european-approval-for-mynzepli-biosimilar-to-eylea]that Mynzepli will be available as a 40 mg/mL solution for injection in a pre-filled syringe and 40 mg/mL solution for injection in a vial.
* The approval is based on a study comparing Mynzepli with the reference biologic Eylea in patients with neovascular age-related macular degeneration..

MORE ON ALVOTECH

* Alvotech 2025 Q2 - Results - Earnings Call Presentation [https://seekingalpha.com/article/4813678-alvotech-2025-q2-results-earnings-call-presentation]
* Alvotech (ALVO) Q2 2025 Earnings Call Transcript [https://seekingalpha.com/article/4813677-alvotech-alvo-q2-2025-earnings-call-transcript]
* Alvotech: A Fast-Expanding Biosimilar Concern [https://seekingalpha.com/article/4800707-alvotech-fast-expanding-biosimilar-concern]
* Alvotech targets 50% U.S. Humira biosimilar market share by year-end as Q2 product revenues rise 77% [https://seekingalpha.com/news/4485540-alvotech-targets-50-percent-u-s-humira-biosimilar-market-share-by-year-end-as-q2-product]
* Alvotech Non-GAAP EPS of $0.49 beats by $0.49 [https://seekingalpha.com/news/4484929-alvotech-non-gaap-eps-of-0_49-beats-by-0_49]